Skip to main content
SpringerLink
Log in

Narcolepsy in the Older Adult

Epidemiology, Diagnosis and Management

  • Therapy in Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Narcolepsy is a disorder of impaired expression of wakefulness and rapid-eye-movement (REM) sleep. This manifests as excessive daytime sleepiness and expression of individual physiological correlates of REM sleep that include cataplexy and sleep paralysis (REM sleep atonia intruding into wakefulness), impaired maintenance of REM sleep atonia (e.g. REM sleep behaviour disorder [RBD]), and dream imagery intruding into wakefulness (e.g. hypnagogic and hypnopompic hallucinations).

Excessive sleepiness typically begins in the second or third decade followed by expression of auxiliary symptoms. Only cataplexy exhibits a high specificity for diagnosis of narcolepsy. While the natural history is poorly defined, narcolepsy appears to be lifelong but not progressive. Mild disease severity, misdiagnoses or long delays in cataplexy expression often cause long intervals between symptom onset, presentation and diagnosis. Only 15–30% of narcoleptic individuals are ever diagnosed or treated, and nearly half first present for diagnosis after the age of 40 years.

Attention to periodic leg movements (PLM), sleep apnoea and RBD is particularly important in the management of the older narcoleptic patient, in whom these conditions are more likely to occur. Diagnosis requires nocturnal polysomnography (NPSG) followed by multiple sleep latency testing (MSLT). The NPSG of a narcoleptic patient may be totally normal, or demonstrate the patient has a short nocturnal REM sleep latency, exhibits unexplained arousals or PLM. The MSLT diagnostic criteria for narcolepsy include short sleep latencies (<8 minutes) and at least two naps with sleep-onset REM sleep.

Treatment includes counselling as to the chronic nature of narcolepsy, the potential for developing further symptoms reflective of REM sleep dyscontrol, and the hazards associated with driving and operating machinery. Elderly narcoleptic patients, despite age-related decrements in sleep quality, are generally less sleepy and less likely to evidence REM sleep dyscontrol.

Nonpharmacological management also includes maintenance of a strict wake-sleep schedule, good sleep hygiene, the benefits of afternoon naps and a programme of regular exercise. Thereafter, treatment is highly individualised, depending on the severity of daytime sleepiness, cataplexy and sleep disruption.

Wake-promoting agents include the traditional psychostimulants. More recently, treatment with the ‘activating’ antidepressants and the novel wake-promoting agent modafinil has been advocated. Cataplexy is especially responsive to antidepressants which enhance synaptic levels of noradrenaline (norepinephrine) and/or serotonin. Obstructive sleep apnoea and PLMs are more common in narcolepsy and should be suspected when previously well controlled older narcolepsy patients exhibit a worsening of symptoms. The discovery that narcolepsy/cataplexy results from the absence of neuroexcitatory properties of the hypothalamic hypocretin-peptidergic system will significantly advance understanding and treatment of the symptom complex in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gelineau J. De la narcolepsie. Gaz Hop (Paris) 1880; 53: 626–8

    Google Scholar 

  2. Henneberg R. Uber genuine Narkolpesie. Neurol Centralbl 1916; 35: 282–90

    Google Scholar 

  3. Vogel G. Studies in psychophysiology of dreams: III. the dream of narcolepsy. Arch Gen Psychiatry 1960; 3: 421–8

    Article  PubMed  CAS  Google Scholar 

  4. Rechtschaffen A, Wolpert E, Dement W. Nocturnal sleep of narcoleptics. Electroencephalogr Clin Neurophysiol 1963; 15: 599–609

    Article  PubMed  CAS  Google Scholar 

  5. Dement W, Rechtschaffen A, Gulevich G. The nature of the narcoleptic sleep attack. Neurology 1966; 16: 18–33

    Article  PubMed  CAS  Google Scholar 

  6. Dantz B, Edgar DM, Dement WC. Circadian rhythms in narcolepsy: studies on a 90 minute day. Electroencephalogr Clin Neurophysiol 1994; 90(1): 24–35

    Article  PubMed  CAS  Google Scholar 

  7. Moscovitch A, Partinen M, Guilleminault C. The positive diagnosis of narcolepsy and narcolepsy’s borderland. Neurology 1993; 43: 55–60

    Article  PubMed  CAS  Google Scholar 

  8. Daniels L. Narcolepsy. Medicine 1934; 13: 1–122

    Google Scholar 

  9. Yoss R, Daly D. Criteria for the diagnosis of the narcoleptic syndrome. Proc Staff Meet Mayo Clin 1957; 32: 320–8

    PubMed  CAS  Google Scholar 

  10. Yoss R, Daly D. Narcolepsy. Med Clin North Am 1960; 44: 953–68

    PubMed  CAS  Google Scholar 

  11. Rye D, Dihenia B, Weissman J, et al. Presentation of narcolepsy after forty. Neurology 1998; 50: 459–65

    Article  PubMed  CAS  Google Scholar 

  12. Hublin C, Kaprio J, Partinen M, et al. The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort. Ann Neurol 1994; 35: 709–16

    Article  PubMed  CAS  Google Scholar 

  13. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998; 50Suppl. 1: S16–22

    Article  PubMed  CAS  Google Scholar 

  14. Ohayon M, Priest R, Zulley J, et al. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002; 58: 1826–3

    Article  PubMed  CAS  Google Scholar 

  15. Lavie P, Peled R. Narcolepsy is a rare disease in Israel. Sleep 1987; 10: 608–9

    PubMed  CAS  Google Scholar 

  16. Honda Y. Census of narcolepsy, cataplexy and sleep life among teenagers in Fujisawa city [abstract]. Sleep Res 1979; 8: 191

    Google Scholar 

  17. Hublin C, Partinen M, Kaprio J, et al. Epidemiology of narcolepsy. Sleep 1994; 17: S7–S12

    PubMed  CAS  Google Scholar 

  18. Silber MH, Rye DB. Solving the mysteries of narcolepsy. Neurology 2001; 56: 1616–8

    Article  PubMed  CAS  Google Scholar 

  19. Kilduff T, Peyron C. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci 2000; 23(8): 359–65

    Article  PubMed  CAS  Google Scholar 

  20. Bourgin P, Huitron-Resendiz S, Spier AD, et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 2000; 20: 7760–5

    PubMed  CAS  Google Scholar 

  21. Ivanov A, Aston-Jones G. Hypocretin/orexin depolarizes and decreases potassium conductance in locus coeruleus neurons. Neuroreport 2000; 11: 1755–8

    Article  PubMed  CAS  Google Scholar 

  22. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6(9): 991–7

    Article  PubMed  CAS  Google Scholar 

  23. Thannickal T, Moore R, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27(3): 469–74

    Article  PubMed  CAS  Google Scholar 

  24. Mignot E, Lin X, Arrigoni J, et al. DQB1-0602 and DQA1-0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and Black Americans. Sleep 1994; 17(8): S60–7

    PubMed  CAS  Google Scholar 

  25. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98(3): 365–76

    Article  PubMed  CAS  Google Scholar 

  26. Kisamuki Y, Chemelli R, Sinton C, et al. The role of orexin receptor type-1 (OX1R) in the regulation of sleep [abstract]. Sleep 2000; 23Suppl. 2: A91

    Google Scholar 

  27. Chemelli R, Willie J, Sinton C, et al. olepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98(4): 437–51

    Article  PubMed  CAS  Google Scholar 

  28. Olafsdottir B, Rye D, Matheson J, et al. Polymorphisms in hypocretin (orexin) pathway genes and narcolepsy. Neurology 2001; 57: 1896–9

    Article  PubMed  CAS  Google Scholar 

  29. Arii J, Kanbayashi T, Tanabe Y, et al. A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor. Neurology 2001; 56(12): 1775–6

    Article  PubMed  CAS  Google Scholar 

  30. Scammell T, Nishino S, Mignot E, et al. Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. Neurology 2001; 56: 1616–8

    Article  Google Scholar 

  31. Aldrich MS, Naylor MW. Narcolepsy associated with lesions of the diencephalon. Neurology 1989; 39: 1505–8

    Article  PubMed  CAS  Google Scholar 

  32. Honda Y, Juji T, Matsuki K, et al. HLA-DR2 and Dw2 in narcolepsy and in other disorders of excessive somnolence without cataplexy. Sleep 1986; 9: 133–42

    PubMed  CAS  Google Scholar 

  33. Neely S, Rosenberg R, Spire J-P, et al. HLA antigens in narcolepsy. Neurology 1987; 37: 1858–60

    Article  PubMed  CAS  Google Scholar 

  34. Mignot E, Tafti M, Dement W, et al. Narcolepsy and immunity. Adv Neuroimmunol 1995; 5: 23–37

    Article  PubMed  CAS  Google Scholar 

  35. Rogers A, Meehan J, Guilleminault C, et al. HLA DR15 (DR2) and DQBl*0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology 1997; 48: 1550–6

    Article  PubMed  CAS  Google Scholar 

  36. Mignot E, Hayduck R, Black J, et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997; 20: 1012–20

    PubMed  CAS  Google Scholar 

  37. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy [letter]. Lancet 2000; 355(9197): 39–40

    Article  PubMed  CAS  Google Scholar 

  38. Dalai M, Schuld A, Haack M, et al. Normal plasma levels of orexin A in narcoleptic patients. Neurology 2001; 56: 1749–51

    Article  Google Scholar 

  39. Kanbayashi T, Inoue Y, Chiba S, et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002; 11: 91–3

    Article  PubMed  Google Scholar 

  40. Mignot E, Lammers G, Ripley B, et al. The role of CSF hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002; 59: 1553–62

    Article  PubMed  Google Scholar 

  41. Anic-Labat S, Guilleminault C, Kraemer HC, et al. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999; 22(1): 77–87

    PubMed  CAS  Google Scholar 

  42. Hussain A, Qadiri M, Rees P, et al. An unusual cause of falls in an elderly patient. Int J Clin Pract 1999; 53(5): 399–400

    PubMed  CAS  Google Scholar 

  43. International Classification of Sleep Disorders. Diagnostic and Coding Manual, Revised. Rochester (MN): American Sleep Disorders Association, 1997

  44. Aldrich M. Narcolepsy. Neurology 1992; 42 (7 Suppl. 6): 34–43

    PubMed  CAS  Google Scholar 

  45. Aldrich MS. The clinical spectrum of narcolepsy and idiopathic hypersomnia. Neurology 1996; 46: 393–401

    Article  PubMed  CAS  Google Scholar 

  46. Ohayon M, Zulley J, Guilleminault C, et al. Prevalence and pathologic associations of sleep paralysis in the general population. Neurology 1999; 52: 1194–200

    Article  PubMed  CAS  Google Scholar 

  47. Douglass A, Hays P, Pazderka E, et al. Florid refractory schizophrenia that turns out to be treatable variants of HLA-associated narcolepsy. J Nerv Ment Dis 1991; 179: 12–7

    Article  PubMed  CAS  Google Scholar 

  48. Jackson C, Bachman D. Narcolepsy-related psychosis misinterpreted as schizophrenia. Neuropsychiatry Neuropsychol Behav Neurol 1996; 9(2): 139–40

    Google Scholar 

  49. Lamphere J, Young D, Roehrs T, et al. Fragmented sleep, daytime somnolence and age in narcolepsy. Clin Electroencephalogr 1989; 20: 49–54

    PubMed  CAS  Google Scholar 

  50. Gosselin A, Montplaisir J, Lesperance P, et al. The effect of age on the MSLT in 137 patients with narcolepsy [abstract]. Sleep Res 1997; 26: 368

    Google Scholar 

  51. Young D, Zorick F, Lamphere J, et al. Fragmented sleep, daytime somnolence and age in narcolepsy [abstract]. Sleep Res 1986; 15: 186

    Google Scholar 

  52. Sangal R, Mitler M, Sangal J. MSLT, MWT, and ESS: indices of sleepiness in 522 drug-free patients with narcolepsy [abstract]. Sleep Res 1997; 26: 492

    Google Scholar 

  53. Guilleminault C, Mignot E, Aldrich M. Prazosin contraindicated in patients with narcolepsy [letter]. Lancet 1988; II: 511

    Article  Google Scholar 

  54. Aldrich M, Rogers A. Exacerbation of human cataplexy by prazosin. Sleep 1989; 12(3): 254–6

    PubMed  CAS  Google Scholar 

  55. Nishino S, Arrigoni J, Valtier D, et al. Dopamine D2 mechanisms in canine narcolepsy. J Neurosci 1991; 11: 2666–71

    PubMed  CAS  Google Scholar 

  56. Baker T, Guilleminault C, Nino-Murcia G, et al. Comparative polysomnographic study of narcolepsy and idiopathic central nervous system hypersomnia. Sleep 1986; 9(1): 232–42

    PubMed  CAS  Google Scholar 

  57. Montplaisir J, Godbout R. Nocturnal sleep of narcoleptic patients: revisited. Sleep 1986; 9: 159–61

    PubMed  CAS  Google Scholar 

  58. Iranzo A, Santamaria J. Hyperkalemic periodic paralysis associated with multiple sleep onset REM periods. Sleep 1999; 22(8): 1123–4

    PubMed  CAS  Google Scholar 

  59. Moriguchi T, Sakurai T, Sambu T, et al. Neurons containing orexin in the lateral hypothalamic area of the adult rat brain are activated by insulin-induced acute hypoglycemia. Neuroscience Letters 1999; 264: 101–4

    Article  PubMed  CAS  Google Scholar 

  60. Chokroverty S. Sleep apnea in narcolepsy. Sleep 1986; 9(1): 250–3

    PubMed  CAS  Google Scholar 

  61. Guilleminault C, Philip P. Tiredness and somnolence despite initial treatment of obstructive sleep apnea syndrome (what to do when an OSAS patient stays hypersomnolent despite treatment). Sleep 1996; 19(9): S117–22

    PubMed  CAS  Google Scholar 

  62. Johns M. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14(6): 540–5

    PubMed  CAS  Google Scholar 

  63. Carskadon M. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986; 9: 519–24

    PubMed  CAS  Google Scholar 

  64. Mitler MM, Carskadon MA, Hirshkowitz M. Evaluating sleepiness. In: Kryger M, Roth T, Dement W, editors. Principles and practice of sleep medicine. 32nd ed. Philadelphia (PA): WB Saunders, 2000: 1251–57

    Google Scholar 

  65. Aldrich M, Chervin R. Predictive value of MSLT REM periods for the diagnosis of narcolepsy [abstract]. Sleep Res 1995; 24: 186

    Google Scholar 

  66. Mitler M, Walsleben J, Sangal R, et al. Sleep latency on the maintenance of wakefulness test (MWT) for 530 patients with narcolepsy while free of psychoactive drugs. Electroencephalogr Clin Neurophysiol 1998; 107: 33–8

    Article  PubMed  CAS  Google Scholar 

  67. Pollmächer T, Mullington J, Lauer C. REM sleep disinhibition at sleep onset: A comparison between narcolepsy and depression. Biol Psychiatry 1997; 42: 713–20

    Article  PubMed  Google Scholar 

  68. Walsh J, Smitson S, Kramer M. Sleep-onset REM sleep: comparison of narcoleptic and obstructive sleep apnea patients. Clin Electroencephalogr 1982; 13: 57–60

    PubMed  CAS  Google Scholar 

  69. Kales A, Cadieux RJ, Soldatos CR, et al. Narcolepsy-cataplexy I. Clinical and electrophysiological characteristics. Arch Neurology 1982; 39: 164–8

    Article  CAS  Google Scholar 

  70. Schenck C, Mahowald M. Motor dyscontrol in narcolepsy: Rapid-eye-movement (REM) sleep without atonia and REM sleep behavior disorder. Ann Neurol 1992; 32: 3–10

    Article  PubMed  CAS  Google Scholar 

  71. van den Hoed J, Kraemer H, Guilleminault C, et al. Disorders of excessive daytime sleepiness: polygraphic and clinical data for 100 patients. Sleep 1981; 4: 23–37

    PubMed  Google Scholar 

  72. Nykamp K, Rosenthal L, Helmus T, et al. Repeated nocturnal sleep latencies in narcoleptic, sleepy and alert subjects. Clin Neurophysiol 1999; 110: 1531–4

    Article  PubMed  CAS  Google Scholar 

  73. Aldrich M. Diagnostic aspects of narcolepsy. Neurology 1988: 50Suppl. 1: S2–7

    Google Scholar 

  74. Mullington J, Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep 1993; 16: 444–56

    PubMed  CAS  Google Scholar 

  75. Helmus T, Rosenthal L, Bishop C, et al. The alerting effects of short and long naps in narcoleptic, sleep deprived, and alert individuals. Sleep 1997; 20: 251–7

    PubMed  CAS  Google Scholar 

  76. Browman Cp, Gujavarty KS, Mitler MM. Tobacco use by narcoleptics and daytime sleep tendency. Drug Alcohol Depend 1984; 14: 23–6

    Article  PubMed  CAS  Google Scholar 

  77. Broughton RJ, Guberman A, Roberts J. Comparison of the psychosocial effects of epilepsy and narcolepsy/cataplexy: a controlled study. Epilepsia 1984; 25(4): 423–33

    Article  PubMed  CAS  Google Scholar 

  78. Kales A, Soldatos C, Bixler E, et al. Narcolepsy-cataplexy: II. psychosocial consequences and associated psychopathology. Arch Neurol 1982; 39: 169–71

    Article  PubMed  CAS  Google Scholar 

  79. Reynolds CF, Christiansen CL, Taska LS, et al. Sleep in narcolepsy and depression: does it all look alike? J Nerv Ment Dis 1983; 171(5): 290–5

    Article  PubMed  Google Scholar 

  80. Rye D, Dihenia B, Bliwise D. Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion. Depress Anxiety 1998; 7: 92–5

    Article  PubMed  CAS  Google Scholar 

  81. American Sleep Disorders Association. Standards of Practice: practice parameters for the use of stimulants in the treatment of narcolepsy. Sleep 1994; 17(4): 348–51

    Google Scholar 

  82. Littner M, Johnson S, McCall W, et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001: 24: 451–66

    PubMed  CAS  Google Scholar 

  83. Koob GF. Stimulants: basic mechanisms and pharmacology. In: Kryger M, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 3rd ed. Philadelphia (PA): WB Saunders, 2000: 419–28

    Google Scholar 

  84. Nishino S, Mao J, Sampathkumaran R, et al. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998; 1(1): 49–61

    PubMed  CAS  Google Scholar 

  85. Berridge C, O’Neil J, Wifler K. Amphetamine acts within the medial basal forebrain to initiate and maintain alert waking. Neuroscience 1999; 93: 885–96

    Article  PubMed  CAS  Google Scholar 

  86. Wisor J, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001; 21(5): 1787–94

    PubMed  CAS  Google Scholar 

  87. Kanbayashi T, Honda K, Kodama T, et al. Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of D- and L-derivatives in canine narcolepsy. Neuroscience 2000; 99(4): 651–9

    Article  PubMed  CAS  Google Scholar 

  88. Guilleminault C. Controversies in sleep physiology and sleep medicine: amphetamines and narcolepsy 1. amphetamines and narcolepsy: use of the Stanford database. Sleep 1993; 16(3): 199–201

    PubMed  CAS  Google Scholar 

  89. Parkes J, Dahlitz M. Controversies in sleep physiology and sleep medicine: amphetamines and narcolepsy 2. amphetamine prescription. Sleep 1993; 16(3): 201–3

    PubMed  CAS  Google Scholar 

  90. Mitler M, Erman M, Hajdukovic R. Controversies in sleep physiology and sleep medicine: amphetamines and narcolepsy 3. the treatment of excessive somnolence with stimulant drugs. Sleep 1993; 16(3): 203–6

    PubMed  CAS  Google Scholar 

  91. Nishino S, Mao J, Sampathkumaran R, et al. Adrenergic, but not dopaminergic, uptake inhibition reduces REM sleep and cataplexy concomitantly [abstract]. Sleep Res 1997; 26: 445

    Google Scholar 

  92. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997; 52(1): 27–78

    Article  PubMed  CAS  Google Scholar 

  93. Wu MF, Gulyani SA, Yau E, et al. Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience 1999; 91(4): 1389–99

    Article  PubMed  CAS  Google Scholar 

  94. Mitler M, Aldrich M, Koob G, et al. ASDA standards of practice: narcolepsy and its treatment with stimulants. Sleep 1994; 17(4): 352–71

    PubMed  CAS  Google Scholar 

  95. Mitler M, Hajdukovic R, Erman M. Treatment of narcolepsy with methamphetamine. Sleep 1993; 16(4): 306–17

    PubMed  CAS  Google Scholar 

  96. Honda Y, Hishikawa Y, Takahashi Y. Long-term treatment of narcolepsy with methylphenidate (Ritalin). Curr Ther Res 1979; 25: 288–98

    Google Scholar 

  97. Mitler M, Shafor R, Hajdukovich R, et al. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 1986; 9(1): 260–4

    PubMed  CAS  Google Scholar 

  98. Mignot E. Pathophysiology of narcolepsy. In: Kryger M, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 3rd ed. Philadelphia (PA): WB Saunders, 2000: 663–75

    Google Scholar 

  99. Honda Y, Hishikawa Y. A long-term treatment of narcolepsy and excessive daytime sleepiness with pemoline (Betanamin). Curr Therap Res 1980; 27: 429–41

    Google Scholar 

  100. Safer DJ, Zito JM, Gardner JE. Pemoline hepatotoxicity and postmarketing surveillance. J Am Acad Child Adolesc Psychiatry 2001; 40: 622–9

    Article  PubMed  CAS  Google Scholar 

  101. Shevell M, Schreiber R. Pemoline-associated hepatic failure: a critical analysis of the literature. Pediatric Neurology 1997; 16: 14–6

    Article  PubMed  CAS  Google Scholar 

  102. Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hyper-somnolence in the rat. J Pharmacol Exp Ther 1997; 283(2): 757–69

    PubMed  CAS  Google Scholar 

  103. Ferraro L, Antonelli T, O’Connor W, et al. Modafinil: an antinarcoleptic drug with differential neurochemical profile to d-amphetamine and dopamine reuptake blockers. Biol Psychiatry 1997; 42: 1181–3

    Article  PubMed  CAS  Google Scholar 

  104. Mignot E, Nishino S, Guilleminault C, et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994: 17(5): 436–7

    PubMed  CAS  Google Scholar 

  105. Scammell T, Estabrooke I, McCarthy M, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000; 20(22): 8620–8

    PubMed  CAS  Google Scholar 

  106. Saletu B, Grunberger J, Linzmayer L, et al. Pharmaco-EEG, psychometric and plasma level studies with two novel alpha-adrenergic stimulants CRL 40476 and 40028 (Adranifil) in elderlies. New Trend Exp Clin Psychiat 1986; II(1): 5–31

    Google Scholar 

  107. Saletu B, Frey R, Krupka M, et al. Differential effects of the new central adrenergic agonist modafinil and d-amphetamine on sleep and early morning behaviour in elderlies. Arzneimittelforschung 1989; 39(II): 1268–73

    PubMed  CAS  Google Scholar 

  108. Billiard M, Besset A, Montplaisir J, et al. Modafinil: a double-blind multicentric study. Sleep 1994; 17: S107–12

    PubMed  CAS  Google Scholar 

  109. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 695–700

    Article  PubMed  CAS  Google Scholar 

  110. Laffont F, Mayer G, Minz M. Modafinil in diurnal sleepiness: a study of 123 patients. Sleep 1994; 17: S113–5

    PubMed  CAS  Google Scholar 

  111. Besset A, Tafti M, Villemin E, et al. The effects of modafinil (300mg) on sleep, sleepiness and arousal in narcoleptic patients. Neurophysiol Clin 1993; 23: 47–60

    Article  PubMed  CAS  Google Scholar 

  112. Besset A, Chetrit M, Carlander B, et al. Use of modafinil in the treatment of narcolepsy: a long term follow-up study. Neurophysiol Clin 1996; 26: 60–6

    Article  PubMed  CAS  Google Scholar 

  113. Broughton R, Fleming J, George C, et al. Randomized, doubleblind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997; 49(2): 444–51

    Article  PubMed  CAS  Google Scholar 

  114. Group UMiNMS. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998; 43: 88–97

    Article  Google Scholar 

  115. Fry J. Treatment modalities for narcolepsy. Neurology 1998; 50Suppl. 1: S43–8

    Article  PubMed  CAS  Google Scholar 

  116. Moachon G, Kanmacher I, Clenet M, et al. Pharmacokinetic profile of modafinil. Drugs Today 1996; 32: 327–37

    CAS  Google Scholar 

  117. Wong Y, King S, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999; 39: 281–8

    PubMed  CAS  Google Scholar 

  118. Gillin J, Post R, Wyatt R, et al. REM inhibitory effect of L-dopa infusion during human sleep. Electroencephalogr Clin Neurophysiol 1973; 35: 181–6

    Article  PubMed  CAS  Google Scholar 

  119. Gunne LM, Lidvall H, Widen L. Preliminary clinical trial with L-dopa in narcolepsy. Psychopharmacologia 1971; 19: 204–6

    Article  PubMed  CAS  Google Scholar 

  120. Boivin D, Montplaisir J. The effects of L-dopa on excessive daytime sleepiness in narcolepsy. Neurology 1991; 41: 1267–9

    Article  PubMed  CAS  Google Scholar 

  121. Mayer G, Meier K, Hephata K. Selegeline hydrochloride treatment in narcolepsy: a double-blind placebo-controlled study. Clin Neuropharmacol 1995; 18(4): 306–19

    Article  PubMed  CAS  Google Scholar 

  122. Hublin C, Partinen M, Heinonen E, et al. Selegiline in the treatment of narcolepsy. Neurology 1994; 44: 2095–101

    Article  PubMed  CAS  Google Scholar 

  123. Reynolds G, Elsworth J, Blau K, et al. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 1978; 6: 542–4

    Article  PubMed  CAS  Google Scholar 

  124. Gillin JC, Horwitz D, Wyatt RJ. Pharmacologic studies of narcolepsy involving serotonin, acetylcholine and monoamine oxidase. In: Guilleminault C, Dement WC, Passouant P, editors. Narcolepsy: Proceedings of the First International Symposium on Narcolepsy, July 1975, Montpellier, France. West Sussex (UK): Johns Wiley & Sons, 1976: 585–604

  125. Knoll J. The possible mechanisms of action of (-) deprenyl in Parkinson’s disease. J Neural Transm 1978; 43: 177–98

    Article  PubMed  CAS  Google Scholar 

  126. Ascher J, Cole J, Colin J-N, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995: 56(9): 395–401

    PubMed  CAS  Google Scholar 

  127. Schmidt H, Clark R, Hyman R. Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. Am J Psychiatry 1977; 134: 183–5

    PubMed  CAS  Google Scholar 

  128. Henry G, Hart H, Kwentus J, et al. Effects of protriptyline on vigilance and information processing in narcolepsy. Psychopharmacol 1988; 95: 109–12

    CAS  Google Scholar 

  129. Mitler M, Hajdukovic R. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 1991; 14(3): 218–20

    PubMed  CAS  Google Scholar 

  130. Fry J, Pressman M, DiPhillipo M, et al. Treatment of narcolepsy with codeine. Sleep 1986; 9(1): 269–74

    PubMed  CAS  Google Scholar 

  131. Mignot E, Renaud A, Nishino S, et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology 1993; 113: 76–82

    Article  PubMed  CAS  Google Scholar 

  132. Larrosa O, de la Llave Y, Bario S, et al. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 2001; 24: 282–5

    PubMed  CAS  Google Scholar 

  133. Langdon N, Shindler J, Parkes J, et al. Fluoxetine in the treatment of cataplexy. Sleep 1986; 9: 371–3

    PubMed  CAS  Google Scholar 

  134. Frey J, Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology 1994; 44: 707–9

    Article  PubMed  CAS  Google Scholar 

  135. Nishino S, Arrigoni J, Shelton J, et al. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep 1993; 16: 706–12

    PubMed  CAS  Google Scholar 

  136. Chen S, Clift S, Dahlitz M, et al. Treatment in the narcoleptic syndrome: self assessment of the action of dexamphetamine and clomipramine. J Sleep Res 1995; 4: 113–8

    Article  PubMed  Google Scholar 

  137. Guilleminault C, Raynal D, Takahaski S, et al. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand 1976; 54: 71–87

    Article  PubMed  CAS  Google Scholar 

  138. Shapiro W. Treatment of cataplexy with clomipramine. Arch Neurol 1975; 32: 653–6

    Article  PubMed  CAS  Google Scholar 

  139. Schachter M, Parkes J. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry 1980: 43: 171–4

    Article  PubMed  CAS  Google Scholar 

  140. Bental E, Lavie P, Sharf B. Sever hypermotility during sleep in treatment of cataplexy with clomipramine. Isr J Med Sci 1979: 15: 607–9

    PubMed  CAS  Google Scholar 

  141. Niiyama Y, Shimizu T, Abe M, et al. Cortical reactivity in REM sleep with tonic mentalis EMG activity induced by clomipramine: an evaluation by slow vertex response. Electroencephalogr Clin Neurophysiol 1993; 86: 247–51

    Article  PubMed  CAS  Google Scholar 

  142. Salin-Pascual R, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997; 58(8): 348–50

    Article  PubMed  CAS  Google Scholar 

  143. Bedard M-A, Montplaisir J, Godbout R, et al. Nocturnal gamma-hydroxybutyrate — effect on periodic leg movements and sleep organization of narcoleptic patients. Clin Neuropharmacol 1989; 12: 29–36

    Article  PubMed  CAS  Google Scholar 

  144. Mamelak M, Scharf M, Woods M. Treatment of narcolepsy with gammahydroxybutyrate: a review of clinical and sleep lab findings. Sleep 1986; 9: 285–9

    PubMed  CAS  Google Scholar 

  145. Scrima L, Hartman P, Johnson F, et al. The effects of gammahydroxybutyrate on the sleep of narcoleptic patients: a double-blind study. Sleep 1990; 13(6): 479–90

    PubMed  CAS  Google Scholar 

  146. Scharf M, Brown D, Woods M, et al. The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. J Clin Psychiatry 1985; 46: 222–5

    PubMed  CAS  Google Scholar 

  147. USXMS Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25: 42–9

    Google Scholar 

  148. Scharf MB, Lai AA, Branigan B, et al. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep 1998; 21(5): 507–14

    PubMed  CAS  Google Scholar 

  149. Boivin D, Montplaisir J, Poirier G. The effects of L-dopa on periodic leg movements and sleep organization in narcolepsy. Clin Neuropharmacol 1989; 12(4): 339–45

    Article  PubMed  CAS  Google Scholar 

  150. Boivin D, Lorrain D, Montplaisir J. Effects of bromocriptine on periodic limb movements in human narcolepsy. Neurology 1993; 43: 2134–6

    Article  PubMed  CAS  Google Scholar 

  151. Mahowald M, Schenck C. REM sleep parasomnias. In: Kryger M, Roth T, Dement W, editors. Principles and practice of sleep medicine. 3rd ed. St Louis: WB Saunders, 2000: 724–43

    Google Scholar 

Download references

Acknowledgements

The authors express their thanks to members of the Emory Sleep Disorders Laboratory: Dr D. L. Bliwise, Lois Fussell, Monique Williams and Gregory Richardson, without whom this work would not have been possible. This work was supported by USPHS grants NS35345 and NS36697. Dr Rye is a member of Cephalon Inc. Speakers Bureau.

Author information

Authors and Affiliations

  1. Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

    Sangeeta S. Chakravorty

  2. Department of Neurology, Emory University School Of Medicine; The Emory Sleep Disorders Center, Atlanta, Georgia, USA

    David B. Rye

Authors
  1. Sangeeta S. Chakravorty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David B. Rye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David B. Rye.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chakravorty, S.S., Rye, D.B. Narcolepsy in the Older Adult. Drugs Aging 20, 361–376 (2003). https://doi.org/10.2165/00002512-200320050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200320050-00005

Keywords

Search

Navigation